** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with "buy/high risk" rating and $52 PT, a ~48% upside to stock's last close
** Brokerage says company's targeted protein degradation technology offers "first-in-class" approaches in the treatment of various inflammatory and immunological diseases
** Company's atopic dermatitis drug KT-621 has shown "robust preclinical data" with potential to achieve "comparable or superior efficacy" to Regeneron REGN.O and Sanofi's SASY.PA Dupixent, Citigroup says
** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a "remarkable ~60% reduction in symptoms", positioning it as a potential "best-in-class" therapy - brokerage
** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price
** Kymera's shares rose 58.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.